Background: We investigated the mechanisms leading to allele dropout-the nonamplification of 1 of the alleles-in PCR-based diagnosis of Wilson disease (WD). Methods: We extracted genomic DNA from blood samples from 6 WD patients (P1-P6) with allele dropouts detected in a previous study of WD in a Hong Kong Chinese population. We amplified the ATP7B gene by PCR and performed direct DNA sequencing of all exons of the ATP7B gene. To support the proposed mechanism of allele dropout, we used proofreading DNA polymerase, primer design avoiding single-nucleotide polymorphism sites, and duplex PCR. Results: Patients P1-P4 were all apparently homozygous for a known disease-causing mutation, c.2975C>T (p.P992L) in exon 13. Patient P5 was apparently homozygous for a novel mutation, c.2524G>A, and patient P6 was apparently homozygous for another known mutation, c.522_523insA (p.K175K-fs). In all cases, we determined that the patients were actually heterozygous for these mutations. Conclusion: Our results confirm that allele dropout is the mechanism causing apparent homozygosity of heterozygous mutations in these WD patients.
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Wilson disease (WD) is an autosomal recessive inherited disorder of abnormal copper metabolism related to mutational inactivation of the ATP7B gene. DNA-based diagnosis of WD has been used for confirmatory diagnosis and carrier detection of WD. In a WD compound heterozygote, if the wild-type allele fails to be amplified by PCR, DNA sequencing or restriction analysis of the PCR products will show apparent homozygosity of the corresponding mutant alleles. This PCR artifact is called allele dropout. In this study, we investigated the mechanisms leading to allele dropout in 6 WD patients from a Hong Kong Chinese population.
After obtaining informed consent, we collected peripheral blood samples from patients P1-P6 and from the parents of P4. Genomic DNA was extracted by use of a QIAamp Blood Kit (Qiagen). We amplified the coding exons and the flanking introns of the ATP7B gene by PCR using a touch-down approach: 94°C for 12 min; 10 cycles of 94°C for 45 s, 66°C for 45 s (1°C decrement for Direct DNA sequencing of all exons of the ATP7B gene indicated that patients P1-P4 were all apparently homozygous for a known disease-causing mutation, c.2975CϾT (p.P992L), in exon 13 and heterozygous for a disease-causing mutation in other exons (see Table 2 in the online Data Supplement). The mother of P4 was also apparently homozygous for c.2975CϾT (see Fig. 1a in the online Data Supplement). The mutation c.2975CϾT abolished the only Btg1 site in the PCR products. The size of the undigested PCR products was 395 bp. In the presence of 2975C, the PCR products were digested into 176-and 219-bp fragments. In patients P1-P4 and the mother of P4, restriction analysis showed only a single fragment of 395 bp, indicating the presence of a homozygous c.2975CϾT mutation in the PCR products (see Fig. 1b in the online Data Supplement). The restriction analysis findings were consistent with the sequencing results.
Because allele dropout was a possible explanation for the apparent c.2975CϾT homozygosity in patients P1-P4, we reviewed the genomic sequence of the ATP7B gene in the National Center for Biotechnology Information (NCBI) human genome database. We found several single-nucleotide polymorphisms (SNPs) in the flanking introns of the ATP7B gene ( Fig. 1) . Interestingly, a IVS12-90G/T (NCBI accession no. rs2296246) is located at the most 3Ј position of the primer ATP7BE13F. The minor allele of the SNP, IVS12-90T, has an estimated frequency of 0.25 in the Hong Kong Chinese population. Because the primer ATP7BE13F contains the major SNP allele, it will have a mismatch with a DNA template having the minor SNP allele, and the disease-causing allele c.2975T will be preferentially amplified in a WD compound heterozygote with a genotype of IVS12-90G/T. To test this assertion, we determined, by direct DNA sequencing, the genotypes of patients P1-P4 at IVS12-90. We found that patients P1-P4 all had the genotype IVS12-90G/T. We also determined the genotypes at IVS12-90 in 3 other WD compound heterozygotes shown by the original PCR and DNA sequencing methods to be heterozygous for c.2975CϾT. In all 3 WD compound heterozygotes, the genotype at IVS12-90 was G/G. This result is consistent with that predicted from the proposed mechanism of allele dropout.
We designed a pair of outer primers, ATP7BE13Fouter and ATP7BE13Router, that enclosed the entire region bounded by the primers ATP7BE13F and ATP7BE13R. Restriction analysis using the outer primer pair showed that patients P1-P4 were actually heterozygous for the c.2975CϾT mutation (shown for patient P4 in Fig. 1b in the online Data Supplement). Using the primers ATP7BE13F and ATP7BE13R as amplification primers, we used DNA polymerase with 3Ј to 5Ј exonuclease activity to restore the amplification of the dropped wild-type exon 13 (see Fig. 1b in the online Data Supplement), a result that supports the proposed mechanism of allele dropout. Taken together, the results confirmed that allele dropout is the mechanism causing apparent homozygosity of c.2975CϾT mutation in patients P1-P4.
Additionally, using the outer primers ATP7BE13Fouter and ATP7BE13Router for PCR and the inner primers ATP7BE13F and ATP7BE13R for sequencing, we found that sequencing the sense strand using the primer ATP7BE13F showed a homozygous c.2975CϾT mutation, whereas sequencing the antisense strand using the primer ATP7BE13R showed a heterozygous c.2975CϾT mutation (see Fig. 2 in the online Data Supplement). Therefore, allele dropout of the wild-type exon 13 can occur in cycle DNA sequencing.
On direct DNA sequencing of all exons of the ATP7B gene, we found that patient P5 was heterozygous for a known disease-causing mutation, c.2602delC (p.P868P-fs), and apparently homozygous for a novel mutation, c.2524GϾA, which changes codon GAT to AAT, which in turn leads to the substitution of aspartic acid at residue position 842 by asparagine, i.e., p.D842N (see Fig. 3a in the online Data Supplement). The mutation c.2524GϾA was not detected in 50 apparently healthy individuals, indicating that c.2524GϾA is probably a disease-causing mutation. Patient P6 was heterozygous for a known disease-causing mutation, c.314CϾA (p.S105X), and apparently homozygous for another known mutation, c.522_ 523insA (p.K175K-fs; see Fig. 3b in the online Data Supplement). Interestingly, the binding site of primer ATP7BE10R, which amplifies c.2524G, is mutated by c.2602delC, and that of the primer ATP7BE2BF, which amplifies the wild-type c.522_523insA, is mutated by c.314CϾA.
To restore amplification of the dropped alleles of patient P5, we designed a mutant reverse primer, ATP7BE10Rmutant, which had the c.2602delC mutation, for duplex PCR. We set up a duplex PCR reaction using primers ATP7BE10R, ATP7BE10Rmutant, and ATP7BE10F. DNA sequencing of the duplex PCR products showed that patient P5 was actually heterozygous for c.2524GϾA (see Fig. 3a in the online Data Supplement). In addition, we designed a new primer pair, ATP7BE10-11F and ATP7BE10-11R, to amplify the entire exons 10 and 11. DNA sequencing of the PCR products also showed that patient P5 was actually heterozygous for c.2524GϾA mutation (see Fig. 3a in the online Data Supplement).
For patient P6, we designed a mutant primer, ATP7BE2BFmutant, which had the c.314A mutation, and sequencing of the duplex PCR products showed that patient P6 was actually heterozygous for the mutation c.522_523insA (see Fig. 3b in the online Data Supplement).
We found that 15 of the 21 exons of the ATP7B gene have SNPs within 250 bp of their 5Ј and 3Ј flanking regions in the NCBI human genome database (Fig. 1) . Three exons-exons 10, 14, and 19 -have SNPs in both the 5Ј and 3Ј regions. Primers having these SNP sites can cause single or double allele dropout of the wild-type or mutant alleles. In addition, we reviewed the primer sequences for PCR-based diagnosis of WD in the literature published since the ATP7B gene was identified (1, 2 ) . We noted several differences between published primer sequences and the genomic sequence currently in the NCBI human genome database (Table 1 ). All changes in these primers are internal, and stringency conditions will determine whether allele dropout occurs. However, the primer sequence differences may contribute to the muta- (1, 9 ) . Interestingly, studies using RT-PCR in colon cancer occult disease detection have consistently suggested that occult disease identified by this technique is clinically significant (1, 9 ) , whereas studies using IHC have led to conflicting results and controversial conclusions (10, 11 ). These controversies have contributed to the failure of acceptance, even in academic settings, of sentinel LN biopsy and/or serial section analysis of LN, including IHC analysis for CRC. The lack of standardized sample preparation procedures and the labor-intensive nature of the analysis have also contributed.
We have previously reported the identification of LN metastases in other solid-organ tumors, using internally controlled, quantitative RT-PCR (QRT-PCR) assays to provide sensitive, objective, molecular staging of LNs (2, (12) (13) (14) . Importantly, we recently demonstrated that this approach can be fully automated, including sample preparation (15 ). These studies have consistently demonstrated that the success of this approach depends on the quality of disease-specific mRNA markers. Surprisingly, no systematic analysis of potential mRNA markers for CRC has been reported. We therefore performed an extensive mRNA marker survey for CRCs. We report several new markers capable of producing highly accurate QRT-PCR analysis of LNs from a CRC patient.
We conducted an extensive literature and public database survey to identify any potential markers relevant to CRC, followed by 2 phases of screening with QRT-PCR. All potential markers entered the primary screening
